Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
Open Access
- 18 January 2021
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2020.00078
Abstract
Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease, including decompensated cirrhosis and hepatocellular carcinoma. Over 95% of patients with HCV infection have achieved sustained virologic response at 12 weeks under the treatment of several pan-genotypic regimens approved for patients with HCV infection. The glecaprevir/pibrentasvir (G/P) regimen has some features that distinguish it from others and is the only 8-week regimen approved for treatment-naive patients and patients experienced in regimens containing (peg)interferon, ribavirin, and/or sofosbuvir, without an HCV NS3/4A protease inhibitor or NS5A inhibitor (except those with genotype 3). This review aims to summarize the efficacy and safety of G/P in HCV-infected patients from clinic trials and real-world studies, including those who have historically been considered difficult to cure.Keywords
This publication has 70 references indexed in Scilit:
- Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trialThe Lancet Infectious Diseases, 2017
- Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trialJournal of Hepatology, 2017
- Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infectionJournal of Hepatology, 2017
- Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult SubjectsThe Journal of Clinical Pharmacology, 2017
- Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsGastroenterology, 2017
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosisJournal of Hepatology, 2017
- Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analysesJournal of Hepatology, 2017
- Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatmentJournal of Hepatology, 2017
- The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug‐drug interactionsUnited European Gastroenterology Journal, 2016
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionThe New England Journal of Medicine, 2015